Literature DB >> 23131589

Expression and distribution of aggrecanases in human larynx: ADAMTS-5/aggrecanase-2 is the main aggrecanase in laryngeal carcinoma.

S Filou1, M Stylianou, I E Triantaphyllidou, T Papadas, N S Mastronikolis, P D Goumas, D J Papachristou, P Ravazoula, S S Skandalis, D H Vynios.   

Abstract

Members of the ADAMTS family of proteases degrade proteoglycans and thereby have the potential to alter tissue architecture and regulate cellular functions. Aggrecanases are the main enzymes responsible for aggrecan degradation, due to their specific cleavage pattern. In this study, the expression status, the macromolecular organization and localization of ADAMTS-1, ADAMTS-4/aggrecanase-1 and ADAMTS-5/aggrecanase-2 in human normal larynx and laryngeal squamous cell carcinoma (LSCC) were investigated. On mRNA level, the results showed that ADAMTS-4 was the highest expressed enzyme in normal larynx, whereas ADAMTS-5 was the main aggrecanase in LSCC presenting a stage-related increase up to stage III (8-fold higher expression compared to normal), and thereafter decreased in stage IV. Accordingly, immunohistochemical analysis showed that ADAMTS-5, but not ADAMTS-4, was highly expressed by carcinoma cells. Sequential extraction revealed an altered distribution and organization of multiple molecular forms (latent, activated and fragmented forms) of the enzymes within the cancerous and their corresponding macroscopically normal laryngeal tissues, compared to the normal ones. Importantly, these analyses indicated that critical macromolecular changes occurred from the earliest LSCC stages not only in malignant parts of the tissue but also in areas that were not in proximity to carcinoma cells and appeared otherwise normal. Overall, the results of the present study show that ADAMTS-5/aggrecanase-2 is the main aggrecanase present in laryngeal carcinoma suggesting a critical role for the enzyme in aggrecan degradation and laryngeal tissue destruction during tumor progression.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23131589     DOI: 10.1016/j.biochi.2012.10.022

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  6 in total

1.  Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma.

Authors:  Young Wha Koh; Sung-Min Chun; Young-Soo Park; Joon Seon Song; Geon Kook Lee; Shin Kwang Khang; Se Jin Jang
Journal:  Tumour Biol       Date:  2016-02-11

Review 2.  ADAMTS-5: A difficult teenager turning 20.

Authors:  Salvatore Santamaria
Journal:  Int J Exp Pathol       Date:  2020-03-27       Impact factor: 1.925

3.  ADAMTS expression in colorectal cancer.

Authors:  Serafula Filou; Aggeliki Korpetinou; Dora Kyriakopoulou; Dimitrios Bounias; Michael Stavropoulos; Panagiota Ravazoula; Dionysios J Papachristou; Achilleas D Theocharis; Demitrios H Vynios
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 4.  Metabolism of cartilage proteoglycans in health and disease.

Authors:  Demitrios H Vynios
Journal:  Biomed Res Int       Date:  2014-07-03       Impact factor: 3.411

5.  microRNA -140-5p inhibits colorectal cancer invasion and metastasis by targeting ADAMTS5 and IGFBP5.

Authors:  Lihui Yu; Ying Lu; Xiaocui Han; Wenyue Zhao; Jiazhi Li; Jun Mao; Bo Wang; Jie Shen; Shujun Fan; Lu Wang; Mei Wang; Lianhong Li; Jianwu Tang; Bo Song
Journal:  Stem Cell Res Ther       Date:  2016-12-01       Impact factor: 6.832

6.  Cleavage of Fibulin-2 by the aggrecanases ADAMTS-4 and ADAMTS-5 contributes to the tumorigenic potential of breast cancer cells.

Authors:  Tania Fontanil; Saúl Álvarez-Teijeiro; M Ángeles Villaronga; Yamina Mohamedi; Laura Solares; Angela Moncada-Pazos; José A Vega; Olivia García-Suárez; Marcos Pérez-Basterrechea; Juana M García-Pedrero; Alvaro J Obaya; Santiago Cal
Journal:  Oncotarget       Date:  2017-02-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.